Gland Pharma Limited (GLAND) — Cash Flow-to-Debt Ratio
Gland Pharma Limited (GLAND) has a Cash Flow-to-Debt Ratio of 0.27x as of September 2025, meaning its operating cash flow of Rs5.93 Billion could theoretically repay 0% of its total liabilities (Rs22.37 Billion) in one year. See GLAND financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Gland Pharma Limited Cash Flow-to-Debt Ratio (2017–2026)
Historical debt coverage capacity for Gland Pharma Limited across 10 annual periods. For the full cash flow conversion analysis, see GLAND operating cash flow.
Annual Cash Flow-to-Debt Ratio for Gland Pharma Limited (2017–2026)
Year-by-year debt coverage analysis for Gland Pharma Limited. Check GLAND cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (INR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | 0.57x | Rs12.31 Billion | Rs21.53 Billion | ▲ +29.7% |
| 2025 | 0.44x | Rs9.15 Billion | Rs20.74 Billion | ▼ -14.3% |
| 2024 | 0.51x | Rs9.97 Billion | Rs19.37 Billion | ▲ +15.7% |
| 2023 | 0.44x | Rs3.64 Billion | Rs8.19 Billion | ▼ -62.0% |
| 2022 | 1.17x | Rs7.91 Billion | Rs6.76 Billion | ▲ +14.6% |
| 2021 | 1.02x | Rs6.05 Billion | Rs5.93 Billion | ▼ -36.0% |
| 2020 | 1.59x | Rs7.01 Billion | Rs4.40 Billion | ▲ +469.1% |
| 2019 | 0.28x | Rs1.85 Billion | Rs6.62 Billion | ▼ -28.1% |
| 2018 | 0.39x | Rs2.02 Billion | Rs5.19 Billion | ▼ -68.6% |
| 2017 | 1.24x | Rs4.76 Billion | Rs3.84 Billion | — |